SGLT2 Inhibitors and Diabetic Retinopathy: Insights from the Management of Nephropathy

Overview

Journal Eye (Lond)

Specialty Ophthalmology

Date 2024 Nov 12

PMID 39533037

Authors

Maria S Varughese

Lakshminarayanan Varadhan

Affiliations

Soon will be listed here.

Citing Articles

Hybrid closed loop and intensive insulin delivery technology: Reviewing the effect of improving 'time in range' glucose levels on diabetic retinopathy.

Varughese M, Nayak A, Varadhan L Eye (Lond). 2025; .

PMID: 39972205 DOI: 10.1038/s41433-025-03730-4.

References

Klen J, Goricar K, Dolzan V . Genetic variability in sodium-glucose cotransporter 2 influences glycemic control and risk for diabetic retinopathy in type 2 diabetes patients. J Med Biochem. 2020; 39(3):276-282. PMC: 7682783. DOI: 10.2478/jomb-2019-0040. View

Huang S, Bair P, Chang S, Kao Y, Chen S, Wang I . Risk of Diabetic Retinopathy in Patients With Type 2 Diabetes After SGLT-2 Inhibitors: A Nationwide Population Cohort Study. Clin Pharmacol Ther. 2023; 115(1):95-103. DOI: 10.1002/cpt.3074. View

Lin D, Lo H, Huang K, Lin T, Lee J, Lin L . Incidence and progression of diabetic retinopathy in patients treated with glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: A population-based cohort study. Diabetes Obes Metab. 2024; 26(10):4386-4396. DOI: 10.1111/dom.15788. View

Wakisaka M, Nagao T . Sodium glucose cotransporter 2 in mesangial cells and retinal pericytes and its implications for diabetic nephropathy and retinopathy. Glycobiology. 2017; 27(8):691-695. PMC: 5881757. DOI: 10.1093/glycob/cwx047. View

Ishibashi R, Inaba Y, Koshizaka M, Takatsuna Y, Tatsumi T, Shiko Y . Sodium-glucose co-transporter 2 inhibitor therapy reduces the administration frequency of anti-vascular endothelial growth factor agents in patients with diabetic macular oedema with a history of anti-vascular endothelial growth factor agent use: A.... Diabetes Obes Metab. 2024; 26(4):1510-1518. DOI: 10.1111/dom.15454. View

Tatsumi T, Oshitari T, Takatsuna Y, Ishibashi R, Koshizaka M, Shiko Y . Sodium-Glucose Co-Transporter 2 Inhibitors Reduce Macular Edema in Patients with . Life (Basel). 2022; 12(5). PMC: 9146993. DOI: 10.3390/life12050692. View

Izzedine H, Bodaghi B, Launay-Vacher V, Deray G . Eye and kidney: from clinical findings to genetic explanations. J Am Soc Nephrol. 2003; 14(2):516-29. DOI: 10.1097/01.asn.0000051705.97966.ad. View

Lahoti S, Nashawi M, Sheikh O, Massop D, Mir M, Chilton R . Sodium-glucose co-transporter 2 inhibitors and diabetic retinopathy: insights into preservation of sight and looking beyond. Cardiovasc Endocrinol Metab. 2021; 10(1):3-13. PMC: 7901818. DOI: 10.1097/XCE.0000000000000209. View

Herat L, Matthews J, Rakoczy E, Schlaich M, Matthews V . Comparing and Contrasting the Effects of the SGLT Inhibitors Canagliflozin and Empagliflozin on the Progression of Retinopathy. Front Biosci (Landmark Ed). 2023; 28(4):83. DOI: 10.31083/j.fbl2804083. View

10.

Lin T, Kang E, Shao S, Lai E, Garg S, Chen K . Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. Diabetes Metab J. 2023; 47(3):394-404. PMC: 10244193. DOI: 10.4093/dmj.2022.0221. View

11.

Cho E, Park S, Han S, Song J, Lee K, Chung Y . Potent Oral Hypoglycemic Agents for Microvascular Complication: Sodium-Glucose Cotransporter 2 Inhibitors for Diabetic Retinopathy. J Diabetes Res. 2019; 2018:6807219. PMC: 6304903. DOI: 10.1155/2018/6807219. View

12.

Wong C, Wong T, Cheng C, Sabanayagam C . Kidney and eye diseases: common risk factors, etiological mechanisms, and pathways. Kidney Int. 2013; 85(6):1290-302. DOI: 10.1038/ki.2013.491. View

13.

Yen F, Cheng-Chung Wei J, Yu T, Hung Y, Hsu C, Hwu C . Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Retinopathy in Patients With Type 2 Diabetes. JAMA Netw Open. 2023; 6(12):e2348431. PMC: 10733799. DOI: 10.1001/jamanetworkopen.2023.48431. View

14.

Su Y, Shao S, Lai E, Lee C, Hung M, Lai C . Risk of diabetic macular oedema with sodium-glucose cotransporter-2 inhibitors in type 2 diabetes patients: A multi-institutional cohort study in Taiwan. Diabetes Obes Metab. 2021; 23(9):2067-2076. DOI: 10.1111/dom.14445. View

15.

Siriyotha S, Lukkunaprasit T, Looareesuwan P, Kunakorntham P, Anothaisintawee T, Nimitphong H . Individual treatment effects of sodium-glucose co-transporter-2 inhibitors on the risk of chronic kidney disease in patients with type 2 diabetes: A counterfactual prediction model based on real-world data. Diabetes Obes Metab. 2024; 26(10):4418-4428. DOI: 10.1111/dom.15793. View

16.

Eleftheriadou A, Riley D, Zhao S, Austin P, Hernandez G, Lip G . Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database. Diabetologia. 2024; 67(7):1271-1282. PMC: 11153282. DOI: 10.1007/s00125-024-06132-5. View

17.

Li J, Hung Y, Bair H, Hsu S, Hsu C, Lin C . Sodium-glucose co-transporter 2 inhibitor add-on therapy for metformin delays diabetic retinopathy progression in diabetes patients: a population-based cohort study. Sci Rep. 2023; 13(1):17049. PMC: 10564914. DOI: 10.1038/s41598-023-43893-2. View

18.

Varadhan L, Jose M, Humphreys T, Brown A . Newer treatments for diabetes mellitus: A caveat with rapid glycaemic improvement and caution regarding changes in retinopathy screening guidelines within the UK NHS programme. J R Coll Physicians Edinb. 2024; 54(2):178-179. DOI: 10.1177/14782715241257970. View

19.

Bohler F, Bohler L, Taranikanti V . Targeting pericyte retention in Diabetic Retinopathy: a review. Ann Med. 2024; 56(1):2398200. PMC: 11404372. DOI: 10.1080/07853890.2024.2398200. View

20.

Wai K, Mishra K, Koo E, Ludwig C, Parikh R, Mruthyunjaya P . Impact of GLP-1 Agonists and SGLT-2 Inhibitors on Diabetic Retinopathy Progression: An Aggregated Electronic Health Record Data Study. Am J Ophthalmol. 2024; 265():39-47. DOI: 10.1016/j.ajo.2024.04.010. View